Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: A re-evaluation

Prostate

Volumn 62, Issue 1, 2005, Pages 34-39

  Michael, Anja ^a   Stephan, Carsten ^a   Kristiansen, Glen ^a   Burckhardt, Mick ^a   Loening, Stefan A ^a   Schnorr, Dietmar ^a   Jung, Klaus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Benign prostatic hyperplasia; Diagnostic validity; Macrophage migration inhibitory factor; Prostate cancer; Prostate specific antigen

Indexed keywords

C REACTIVE PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; DIAGNOSTIC PROCEDURE; EVALUATION; HUMAN; INFORMATION; LOGISTIC REGRESSION ANALYSIS; MACROPHAGE MIGRATION; MAJOR CLINICAL STUDY; MALE; MIGRATION INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

EID: 10144229122     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20104     Document Type: Article

References (16)

1. Kumar-Sinha C, Rhodes DR, Yu J, Chinnaiyan AM. Prostate cancer biomarkers: A current perspective. Expert Rev Mol Diagn 2003;3:459-470.
2. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
3. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - What we have learned and where we are going. J Urol 1999;162:293-306.
4. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-954.
5. Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:1133-1147.
6. Meyer-Siegler K, Fattor RA, Hudson PB. Expression of macrophage migration inhibitory factor in the human prostate. Diagn Mol Pathol 1998;7:44-50.
7. Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M. Fibroblast growth factors and their receptors in urological cancers: Basic research and clinical implications. Eur Urol 2003;43:309-319.
8. Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol 2000;10:359-366.
9. del Vecchio MT, Tripodi SA, Arcuri F, Pergola L, Hako L, Vatti R, Cintorino M. Macrophage migration inhibitory factor in prostatic adenocarcinoma: Correlation with tumor grading and combination endocrine treatment-related changes. Prostate 2000;45:51-57.
10. Meyer-Siegler KL, Bellino MA, Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 2002;94:1449-1456.
11. Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LF, Lein M, Sinha P, Loening SA, Jung K. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002;48:1279-1287.
12. Sobin LH, Wittekind C. TNM classification of malignant tumours. 5th edition. New York: Wiley-Liss; 1997. pp 170-173.
13. Solberg HE. Approved recommendations on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determinations of reference limits. J Clin Chem Clin Biochem 1987;25:645-656.
14. Isidori AM, Kaltsas GA, Korbonits M, Pyle M, Gueorguiev M, Meinhardt A, Metz C, Petrovsky N, Popovic V, Bucala R, Grossman AB. Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease. J Clin Endocrinol Metab 2002;87:1834-1840.
15. Murakami H, Akbar SM, Matsui H, Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: Clinical implications and pathogenic significance. Eur J Clin Invest 2001;31:337-343.
16. Meyer-Siegler K, Hudson PB. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 1996;48:448-452.